-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $56

Benzinga·11/05/2026 15:54:59
Listen to the news
Guggenheim analyst Michael Schmidt maintains UroGen Pharma (NASDAQ:URGN) with a Buy and lowers the price target from $58 to $56.